Janssen Research & Development
Scientific Director
The Janssen Pharmaceutical Companies of Johnson & Johnson Oct 2013 - Aug 2015
Senior Director
Johnson & Johnson Aug 2005 - Oct 2013
Scientific Director and Fellow
Icagen Feb 1998 - Jul 2005
Group Leader
Ici Pharmaceuticals Aug 1986 - Aug 1995
Research Scientist
Education:
The University of Manchester 1983 - 1986
Bachelors, Bachelor of Science, Physiology, Pharmacology
University of Birmingham
Doctorates, Doctor of Philosophy, Physiology
Interests:
Kids Cooking Electronics Traveling Sewing Outdoors Home Improvement Reading Crafts Gourmet Cooking Sports Golf Travel Collecting Home Decoration
Timothy J. Jegla - Durham NC Alan Wickenden - Cary NC
Assignee:
ICAgen, Incorporated - Durham NC
International Classification:
C12N 1512
US Classification:
435 691, 4353201, 435325, 435 6, 536 235
Abstract:
The invention provides isolated nucleic acid and amino acid sequences of hElk, antibodies to hElk, methods of detecting hElk, methods of screening for voltage-gated potassium channel activators and inhibitors using biologically active hElk, and kits for screening for activators and inhibitors of voltage-gated potassium channels comprising hElk.
The invention provides isolated nucleic acid and amino acid sequences of BK beta 2, BK beta 3, and BK beta 4, antibodies to the BK beta subunits, methods of detecting the BK beta subunits, methods of screening for modulators of Slo potassium channels comprising BK beta subunits, and kits for screening for activators and inhibitors of the Slo family potassium channels comprising BK beta subunits.
Compounds which are useful as potassium channel inhibitors and which because of their slow off-rates are especially useful for the treatment of cardiac arrhythmias are described.
Timothy J. Jegla - Durham NC Alan Wickenden - Cary NC
Assignee:
Icagen, Incorporated - Durham NC
International Classification:
C07K 1400
US Classification:
530350, 530300
Abstract:
The invention provides isolated nucleic acid and amino acid sequences of hElk, antibodies to hElk, methods of detecting hElk, methods of screening for voltage-gated potassium channel activators and inhibitors using biologically active hElk, and kits for screening for activators and inhibitors of voltage-gated potassium channels comprising hElk.